The lack of effect on different measures of coronary plaque reinforce the need for a large CV outcomes trial in these ...

The notifications show promise for getting more patients at least evaluated by a multidisciplinary heart team within 90 days.

News from ACC 2026 dominates our most-read list, along with the dyslipidemia guidelines, Lp(a) vs CAC, and apixaban for VTE.

In the CORALreef AddOn study, roughly 80% of high-risk patients achieved an LDL target of less than 55 mg/dL by 8 weeks.

Helping patients get groceries and make meals while staying on a DASH-approved diet not only helped, but people liked it, too ...

The results run counter to ABYSS but align with other data showing beta-blockers shouldn’t continue indefinitely after MI.

The results, which are mostly relevant to an older population, address a common dilemma for aortic stenosis patients with CAD ...

Unique in its focus on adolescents, the trial shows the cardiac myosin inhibitor safely reduces LVOT in the pediatric ...

The question remains: what will it take to prove that any protection device is having a meaningful impact on stroke risk?

The final results of RECOVERY add support to addressing severe aortic stenosis right away rather than waiting for symptoms.

(CMI), a global leader in innovative drug-delivery technology across vascular interventions, proudly announces the presentation of the world’s largest randomised controlled trial of a Sirolimus-coated ...

NEW ORLEANS, LA—Spironolactone did not improve clinical outcomes in patients who had heart failure with either mildly reduced or preserved ejection fraction (HFmrEF and HFpEF, respectively) in the ...